-
11.发明授权
公开(公告)号：US5631963A
公开(公告)日：1997-05-20
申请号：US331762
申请日：1994-10-31
Applicant: Matthias Herrmann
Inventor： Matthias Herrmann
CPC classification number: H04B1/1661 , H04B1/1027 , Y10S977/872
Abstract: A circuit arrangement for recognizing adjacent channel interference in a stereo radio receiver, in which a stereo multiplex signal is present. An adjacent channel interference signal is obtained as a function of a direct voltage portion of the stereo multiplex signal and as a function of the spectral components of the stereo multiplex signal above 60 kHz.
Abstract translation: 用于识别在其中存在立体声多路复用信号的立体声无线电接收机中的相邻信道干扰的电路装置。 作为立体声多路复用信号的直接电压部分的函数，并且作为高于60kHz的立体声多路复用信号的频谱分量的函数，获得相邻信道干扰信号。
-
公开(公告)号：US09002037B2
公开(公告)日：2015-04-07
申请号：US13531373
申请日：2012-06-22
Applicant: Alfons Dehe , Matthias Herrmann , Ulrich Krumbein , Stefan Barzen , Wolfgang Klein , Wolfgang Friza , Martin Wurzer
Inventor： Alfons Dehe , Matthias Herrmann , Ulrich Krumbein , Stefan Barzen , Wolfgang Klein , Wolfgang Friza , Martin Wurzer
CPC classification number: B81B7/0029 , B81B2201/0257 , B81B2203/0127 , H01L2224/48091 , H01L2224/48137 , H01L2224/8592 , H01L2924/15151 , H01L2924/16152 , H04R7/18 , H04R19/005 , H04R2307/207 , H01L2924/00014
Abstract: A MEMS structure includes a backplate, a membrane, and an adjustable ventilation opening configured to reduce a pressure difference between a first space contacting the membrane and a second space contacting an opposite side of the membrane. The adjustable ventilation opening is passively actuated as a function of the pressure difference between the first space and the second space.
Abstract translation: MEMS结构包括背板，膜和可调节的通风口，其被配置为减小接触膜的第一空间与接触膜的相对侧的第二空间之间的压力差。 根据第一空间和第二空间之间的压差，被调节的通风口被动地致动。
-
13.发明申请INJECTION VALVE, METHOD FOR ITS PRODUCTION, AND APPARATUS FOR PERFORMING THE METHOD 有权注射阀，其制造方法以及用于执行该方法的装置公开(公告)号：US20100180442A1
公开(公告)日：2010-07-22
申请号：US12666190
申请日：2008-06-17
Applicant: Bernhard Zeiss , Wilhelm Christ , Ralf Kuebler , Alfred Hoch , Matthias Herrmann , Lars Ulrich
Inventor： Bernhard Zeiss , Wilhelm Christ , Ralf Kuebler , Alfred Hoch , Matthias Herrmann , Lars Ulrich
CPC classification number: F02M61/168 , B21K1/24 , C21D1/10 , C21D1/18 , C21D1/25 , F02M61/18 , F02M2200/02 , F02M2200/9061 , Y02P10/253 , Y10T29/49405 , Y10T29/49409
Abstract: The invention relates to a method for producing an injection valve for liquids, preferably an injection valve for injecting fuel into a combustion chamber of an internal combustion engine. The injection valve has a valve body, with a valve seat which is formed therein, and a valve needle which interacts with the valve seat in order to open and close at least one injection opening. The injection valve is produced by means of the following method steps: producing the valve body from steel, hardening the valve body, annealing a partial region of the valve body at an annealing temperature. The device for carrying out the method according to the invention has an inductive annealing generator which generates a suitable alternating current for operating a coil, in the magnetic field of which coil the valve body can be heated for annealing.
Abstract translation: 本发明涉及一种用于生产用于液体的喷射阀的方法，优选地是用于将燃料喷射到内燃机的燃烧室中的喷射阀。 喷射阀具有形成有阀座的阀体和与阀座相互作用以打开和关闭至少一个喷射开口的阀针。 注射阀通过以下方法步骤制造：从钢制造阀体，硬化阀体，在退火温度下退火阀体的局部区域。 用于执行根据本发明的方法的装置具有感应退火发生器，其产生用于操作线圈的合适的交流电流，在该磁体的磁场中，阀体可以被加热用于退火。
-
14.发明申请EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE 失效EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用公开(公告)号：US20090220479A1
公开(公告)日：2009-09-03
申请号：US12089627
申请日：2006-09-30
Applicant: Detlef Kozian , Matthias Herrmann
Inventor： Detlef Kozian , Matthias Herrmann
IPC: A61K38/46 , C12N9/14 , C12N15/11 , C12N15/00 , C12N5/06 , A01K67/027 , C07K16/18 , C12P21/02 , C12Q1/68 , C12Q1/34 , C40B30/00
CPC classification number: C12N9/0071
Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Abstract translation: 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病，特别是中风，长期可逆性缺血性神经功能缺损（PRIND）， 经皮缺血发作（TIA），心肌梗死和/或早期心肌梗死。
-
15.发明申请Method of Diagnosis of a Predisposition to Develop Thrombotic Disease and Its Uses 失效诊断血栓形成疾病倾向的方法及其应用公开(公告)号：US20080038722A1
公开(公告)日：2008-02-14
申请号：US10592692
申请日：2005-03-16
Applicant: Detlef Kozian , Matthias Herrmann , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
Inventor： Detlef Kozian , Matthias Herrmann , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
IPC: C12Q1/68
CPC classification number: C12Q1/6883 , C12Q2600/156
Abstract: The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
Abstract translation: 本发明涉及诊断发生血栓形成疾病的倾向，测试系统及其用于诊断倾向于发展血栓形成性疾病的用途的方法，以诊断P 启动子变体及其用于筛选抗血栓形成剂的用途，以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法，或用于调整治疗或预防剂量的抗血栓形成剂 血栓形成剂。
-
Patent Agency Ranking
公开(公告)号：US06673834B2
公开(公告)日：2004-01-06
申请号：US10300963
申请日：2002-11-21
Applicant: Michael Kurz , Matthias Herrmann , Luigi Toti , Laszlo Vertesy
Inventor： Michael Kurz , Matthias Herrmann , Luigi Toti , Laszlo Vertesy
IPC: A61K31336
CPC classification number: C12R1/645 , C07D303/34 , C12P17/02
Abstract: Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases in which high blood platelet aggregations occur.
Abstract translation: 式I化合物适用于生产用于预防和治疗出现高血小板聚集的疾病的药物。
-
17.发明授权Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments 有权作为PAR1抑制剂的三唑鎓盐，其制备和用作药物公开(公告)号：US08853206B2
公开(公告)日：2014-10-07
申请号：US13452146
申请日：2012-04-20
Applicant: Uwe Heinelt , Volkmar Wehner , Matthias Herrmann , Karl Schoenafinger , Henning Steinhagen
Inventor： Uwe Heinelt , Volkmar Wehner , Matthias Herrmann , Karl Schoenafinger , Henning Steinhagen
IPC: C07D249/00 , C07D413/06 , C07D487/04 , C07D471/04 , A61P7/00
CPC classification number: C07D487/04 , C07D471/04
Abstract: The invention relates to novel compounds of formula I where X, A−, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract translation: 本发明涉及式I的新化合物，其中X，A，Q 1，Q 2，Q 3，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9各自定义如下。 式I的化合物具有抗血栓形成活性并特别抑制蛋白酶活化的受体1（PAR1）。 本发明还涉及制备式I化合物及其作为药物的用途的方法。
-
18.发明授权Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments 有权作为PAR1抑制剂的三唑鎓盐，其制备和用作药物公开(公告)号：US08198272B2
公开(公告)日：2012-06-12
申请号：US12851219
申请日：2010-08-05
Applicant: Uwe Heinelt , Volkmar Wehner , Matthias Herrmann , Karl Schoenafinger , Henning Steinhagen
Inventor： Uwe Heinelt , Volkmar Wehner , Matthias Herrmann , Karl Schoenafinger , Henning Steinhagen
IPC: C07D487/04 , C07D413/10 , A61K31/5025 , A61K31/5355 , A61P7/00 , A61P9/10 , A61P29/00 , A61P37/08 , A61P3/14
CPC classification number: C07D487/04 , C07D471/04
Abstract: The invention relates to novel compounds of formula I where X, A−, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract translation: 本发明涉及式I的新化合物，其中X，A，Q 1，Q 2，Q 3，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9各自定义如下。 式I的化合物具有抗血栓形成活性并特别抑制蛋白酶活化的受体1（PAR1）。 本发明还涉及制备式I化合物及其作为药物的用途的方法。
-
19.发明授权EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease 失效EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途公开(公告)号：US08114398B2
公开(公告)日：2012-02-14
申请号：US12089627
申请日：2006-09-30
Applicant: Detlef Kozian , Matthias Herrmann
Inventor： Detlef Kozian , Matthias Herrmann
CPC classification number: C12N9/0071
Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Abstract translation: 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病，特别是中风，长期可逆性缺血性神经功能缺损（PRIND）， 经皮缺血发作（TIA），心肌梗死和/或早期心肌梗死。
-
公开(公告)号：US08084198B2
公开(公告)日：2011-12-27
申请号：US11913873
申请日：2006-05-03
Applicant: Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
Inventor： Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC classification number: C12Q1/6883 , C12Q1/6897 , C12Q2600/156 , C12Q2600/158
Abstract: The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined.
Abstract translation: 在GIP基因的位置（97）处使用单核苷酸多态性（SNP）来鉴定从被检查个体获取的生物样品中的心血管疾病或发展心血管疾病的风险增加。
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.024 seconds)
